Markus Anliker

921 total citations
40 papers, 570 citations indexed

About

Markus Anliker is a scholar working on Immunology, Hematology and Infectious Diseases. According to data from OpenAlex, Markus Anliker has authored 40 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 9 papers in Hematology and 6 papers in Infectious Diseases. Recurrent topics in Markus Anliker's work include Complement system in diseases (14 papers), Blood groups and transfusion (7 papers) and Renal Diseases and Glomerulopathies (6 papers). Markus Anliker is often cited by papers focused on Complement system in diseases (14 papers), Blood groups and transfusion (7 papers) and Renal Diseases and Glomerulopathies (6 papers). Markus Anliker collaborates with scholars based in Germany, Austria and United States. Markus Anliker's co-authors include Hubert Schrezenmeier, Britta Höchsmann, Christof Weinstock, Christoph Q. Schmidt, Thomas Simmet, John D. Lambris, Daniel Ricklin, A Bollinger, F Mahler and Inge von Zabern and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Markus Anliker

40 papers receiving 551 citations

Peers

Markus Anliker
Enrique Esteve‐Valverde Spain
Sarah E. Sartain United States
Luciana Parente Costa Seguro Brazil
Bettina H. Ault United States
Pirkka T. Pekkarinen Finland
Han Joo Baek South Korea
Carmine Pecoraro Italy
Thomas Crépin France
Katerina Laskari Greece
Anna V. Murphy United Kingdom
Enrique Esteve‐Valverde Spain
Markus Anliker
Citations per year, relative to Markus Anliker Markus Anliker (= 1×) peers Enrique Esteve‐Valverde

Countries citing papers authored by Markus Anliker

Since Specialization
Citations

This map shows the geographic impact of Markus Anliker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Anliker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Anliker more than expected).

Fields of papers citing papers by Markus Anliker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Anliker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Anliker. The network helps show where Markus Anliker may publish in the future.

Co-authorship network of co-authors of Markus Anliker

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Anliker. A scholar is included among the top collaborators of Markus Anliker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Anliker. Markus Anliker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garg, Brijesh K., Britta Höchsmann, Hubert Schrezenmeier, et al.. (2024). Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways. Journal of Biological Chemistry. 300(4). 105784–105784. 4 indexed citations
2.
Weißenbacher, Annemarie, Markus Anliker, Julia Hofmann, et al.. (2024). Expression of sPD-L1 levels in an ex vivo liver perfusion model. Clinical & Experimental Immunology. 219(1). 1 indexed citations
3.
Salvador, Christina, Andreas Meryk, Benjamin Hetzer, et al.. (2023). Immature platelet fraction predicts early marrow recovery after severe chemotherapy associated neutropenia. Scientific Reports. 13(1). 3371–3371. 1 indexed citations
4.
Anliker, Markus, Lorin Loacker, Susanne Häfner, et al.. (2022). Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation. The Journal of Immunology. 208(5). 1248–1258. 3 indexed citations
5.
Egger, Alexander, Wolfgang Prokop, Manfred Nairz, et al.. (2021). Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clinical Chemistry and Laboratory Medicine (CCLM). 59(8). 1453–1462. 36 indexed citations
6.
Egger, Alexander, Wolfgang Prokop, Manfred Nairz, et al.. (2021). Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay. Clinical Chemistry and Laboratory Medicine (CCLM). 59(6). 1143–1154. 16 indexed citations
7.
Lanser, Lukas, Francesco Burkert, Alexander Egger, et al.. (2021). Testosterone Deficiency Is a Risk Factor for Severe COVID-19. Frontiers in Endocrinology. 12. 694083–694083. 38 indexed citations
8.
Egger, Alexander, Barbara Holzer, Christoph Winkler, et al.. (2021). Borderline and weakly positive antibody levels against the S-protein of SARS-CoV-2 exhibit limited agreement with virus neutralization titres. SHILAP Revista de lepidopterología. 2(1). 100058–100058. 5 indexed citations
9.
Höchsmann, Britta, Markus Anliker, Christof Weinstock, et al.. (2019). Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients. Frontiers in Immunology. 10. 1639–1639. 15 indexed citations
10.
Schmidt, Christoph Q., Eva-Maria Nichols, Mario Hebecker, et al.. (2016). Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology. 221(4). 503–511. 24 indexed citations
11.
Anliker, Markus, Edimara S. Reis, Markus Huber‐Lang, et al.. (2016). Evaluation of factor H (FH), miniFH and the Fc-fusion protein Fc-miniFH in pharmacokinetic studies and different in vitro models of complement mediated diseases. Immunobiology. 221(10). 1217–1218. 1 indexed citations
12.
Anliker, Markus, et al.. (2015). Resident Assessment Instrument in der Schweiz. Zeitschrift für Gerontologie und Geriatrie. 48(2). 114–120. 10 indexed citations
13.
Weinstock, Christof, Markus Anliker, & I. von Zabern. (2015). CD59: A long-known complement inhibitor has advanced to a blood group system. Immunohematology. 31(4). 145–151. 12 indexed citations
14.
Kaehler, Stefan T., H. Baumgärtner, Markus Anliker, et al.. (2011). Prevalence of hypovitaminosis D and folate deficiency in healthy young female Austrian students in a health care profession. European Journal of Nutrition. 51(8). 1021–1031. 9 indexed citations
15.
Weiler, Stefan, Gerda Falkensammer, Angelika Hammerer‐Lercher, et al.. (2009). Pulmonary Epithelial Lining Fluid Concentrations after Use of Systemic Amphotericin B Lipid Formulations. Antimicrobial Agents and Chemotherapy. 53(11). 4934–4937. 21 indexed citations
16.
Moser, Urs, et al.. (2008). Ein Doppler-Ultraschall-Gerät zur Bestimmung des Blut-Volumenflusses. Ultraschall in der Medizin - European Journal of Ultrasound. 13(2). 77–79. 7 indexed citations
17.
18.
Weder, P., Markus Anliker, P. Itin, & Mario Bargetzi. (2004). Familial Cutaneous Mycosis fungoides: Successful Treatment with a Combination of Gemcitabine and Alemtuzumab. Dermatology. 208(3). 281–283. 10 indexed citations
19.
Exner, G. Ulrich, A Prader, U. Elsasser, et al.. (1980). Hypophosphatemic vitamin D resistant rickets (phosphate diabetes): bone mineral problems studied by 125I-computed tomography and microradiography.. PubMed. 35(1). 39–49. 9 indexed citations
20.
Mahler, F, et al.. (1979). Blood pressure fluctuations in human nailfold capillaries. American Journal of Physiology-Heart and Circulatory Physiology. 236(6). H888–H893. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enrique Esteve‐Valverde Breakdown of academic impact, for papers by Sarah E. Sartain Breakdown of academic impact, for papers by Luciana Parente Costa Seguro Breakdown of academic impact, for papers by Bettina H. Ault Breakdown of academic impact, for papers by Pirkka T. Pekkarinen Breakdown of academic impact, for papers by Han Joo Baek Breakdown of academic impact, for papers by Carmine Pecoraro Breakdown of academic impact, for papers by Thomas Crépin Breakdown of academic impact, for papers by Katerina Laskari Breakdown of academic impact, for papers by Anna V. Murphy
Rankless by CCL
2026